Dr. Usman's Cardiology Notes

  Management of Warfarin-Associated Bleeding --- Introduction Warfarin remains a widely used oral anticoagulant for conditions such as atrial fibrillation, venous thromboembolism, and prosthetic heart valves. However, bleeding is its most significant complication, ranging from minor mucosal bleeding to life-threatening hemorrhage. Prompt recognition and appropriate reversal of anticoagulation are critical to reduce morbidity and mortality. --- Pathophysiology Warfarin inhibits vitamin K–dependent clotting factors: II, VII, IX, and X, along with proteins C and S. Excess anticoagulation (elevated INR) predisposes to bleeding due to impaired coagulation cascade function. --- Initial Assessment Key Steps: Assess severity of bleeding Check INR level Evaluate hemodynamic status Identify site of bleeding Review warfarin dose and drug interactions --- Classification of Bleeding Severity 1. Minor Bleeding Epistaxis, gum bleeding, bruising No hemodynamic compromise 2. Major Bleeding Hemoglob...

  Aortic Regurgitation (AR) Grading on Echocardiography Aortic regurgitation assessment on echocardiography is multiparametric and integrative. No single parameter should be used in isolation—severity is determined by combining qualitative, semi-quantitative, and quantitative findings along with ventricular response. --- 🔴 1. Pathophysiology Insight (Why grading matters) AR causes diastolic backflow from aorta → LV Leads to: Volume overload LV dilatation Progressive LV systolic dysfunction Acute AR behaves differently from chronic AR → always interpret in context --- 🔵 2. Core Echocardiographic Windows PLAX (Parasternal Long Axis) → jet origin, LV size PSAX (Aortic level) → cusp morphology Apical 5-chamber / 3-chamber → Doppler alignment Suprasternal / Descending aorta view → flow reversal --- 🟣 3. Qualitative Assessment Color Doppler Jet Characteristics Mild AR Small, narrow jet Limited to LVOT Moderate AR Intermediate jet size Severe AR Large jet Penetrates deep into LV cavity...

  Lipoprotein(a) — Latest Guidelines (2026 Update) 1. Who Should Be Tested? (Major Change 🔑) All adults should have Lp(a) measured at least once in lifetime (ACC/AHA 2026, ESC/EAS 2025)  Earlier selective testing → now shift toward universal screening Strong indications: Premature ASCVD Family history of early CAD Recurrent events despite optimal LDL Calcific aortic stenosis 👉 Lp(a) is genetically determined & stable, so one-time test is usually enough  --- 2. Risk Thresholds (Important Exam Point) Lp(a) Level Interpretation <30 mg/dL Normal 30–49 mg/dL Intermediate ≥50 mg/dL (≥125 nmol/L) High / Risk-enhancing ≥250 nmol/L Very high risk (~2× ASCVD risk) ≥50 mg/dL is now universally accepted cutoff across guidelines  Higher levels → progressively higher risk (no strict threshold effect)  --- 3. Role in Risk Stratification Lp(a) is now considered: ✅ Independent causal risk factor for: Atherosclerotic cardiovascular disease (ASCVD) Stroke Calcific aortic ...

  CHA₂DS₂-VASc Score in Non-Valvular Atrial Fibrillation Comprehensive, Guideline-Oriented Clinical Guide --- Introduction Atrial Fibrillation (AF) is the most common sustained arrhythmia encountered in clinical practice and is strongly associated with thromboembolic complications, particularly ischemic stroke. In patients with non-valvular AF (i.e., absence of moderate–severe mitral stenosis or mechanical prosthetic valves), stroke risk is not uniform—hence the need for structured risk stratification. The CHA₂DS₂-VASc score is the most widely recommended tool for estimating stroke risk and guiding anticoagulation therapy. --- What is the CHA₂DS₂-VASc Score? The CHA₂DS₂-VASc score is a clinical prediction rule that refines stroke risk assessment beyond older models like CHADS₂ by incorporating additional vascular and demographic risk factors. It estimates the annual risk of stroke or systemic embolism in patients with non-valvular AF. --- Components of CHA₂DS₂-VASc Score Risk Facto...

Pulmonary Vein Doppler (PW) – Detailed Clinical Guide-- 🔹 What is Pulmonary Vein Doppler? Pulsed-wave Doppler of pulmonary veins assesses left atrial (LA) pressure, compliance, and LV diastolic function by analyzing blood flow from pulmonary veins into the LA. Performed in: Apical 4-chamber view Sample volume: ~1 cm inside pulmonary vein (usually right upper pulmonary vein) --- 🔹 Normal Pulmonary Vein Waveform Components: 1. S wave (Systolic forward flow) Blood flows into LA during LV systole Reflects: LA relaxation Mitral annular descent 2. D wave (Diastolic forward flow) Occurs during early LV diastole Represents passive LV filling 3. Ar wave (Atrial reversal) Flow reversal into pulmonary vein during atrial contraction Reflects LV end-diastolic pressure --- 🔹 Normal Values Parameter Normal S > D Yes S/D ratio > 1 Ar duration < Mitral A duration Ar velocity < 35 cm/s --- 🔹 Interpretation in Diastolic Dysfunction 🟢 Grade I (Impaired Relaxation) S > D (prominent) Red...

Management of Dyslipidemia 1. Risk Stratification (Foundation) Management is driven by overall cardiovascular risk rather than LDL alone Major risk categories: Established ASCVD (very high risk) Diabetes mellitus Severe hypercholesterolemia (LDL ≥190 mg/dL) Primary prevention based on risk calculators --- 2. Lifestyle Modification (First-line for all) Diet Reduce saturated & trans fats Increase fiber (fruits, vegetables, whole grains) Mediterranean/DASH-style diet Limit refined sugars Exercise ≥150 min/week moderate intensity Weight Target BMI <25 kg/m² Others Smoking cessation Limit alcohol --- 3. Pharmacologic Therapy A. Statins (First-line) ↓ LDL by 30–60% Stabilize plaques High-intensity statins Atorvastatin 40–80 mg Rosuvastatin 20–40 mg Indications ASCVD → high-intensity LDL ≥190 → high-intensity Diabetes (age 40–75) → moderate/high --- B. Non-Statin Therapies Ezetimibe Add if LDL target not achieved with statin PCSK9 inhibitors Alirocumab, Evolocumab For very high-risk or...

NOAC Antidotes: Reversal Strategies for Direct Oral Anticoagulants (DOACs) Introduction Non–vitamin K antagonist oral anticoagulants (NOACs), also known as DOACs, are widely used for stroke prevention in atrial fibrillation and treatment of venous thromboembolism. Despite their favorable safety profile compared to warfarin, major bleeding and urgent procedural needs require rapid reversal strategies. --- Classification of NOACs Direct Thrombin Inhibitor Dabigatran Factor Xa Inhibitors Rivaroxaban Apixaban Edoxaban --- Specific Antidotes 1. Dabigatran Reversal Antidote: Idarucizumab Mechanism: Monoclonal antibody fragment that binds dabigatran with very high affinity Dose: 5 g IV (2 × 2.5 g boluses) Onset: Immediate Indications: Life-threatening bleeding Emergency surgery --- 2. Factor Xa Inhibitor Reversal Antidote: Andexanet alfa Mechanism: Recombinant modified factor Xa decoy protein Targets: Rivaroxaban, Apixaban (limited data for Edoxaban) Administration: Bolus + infusion (dose dep...